达格列净联合沙库巴曲缬沙坦钠治疗急性心肌梗死经皮冠状动脉介入治疗术后心力衰竭患者的疗效
Efficacy of Dagliflozin combination with Sarcovalsartan Sodium in the Treatment of Heart Failure after PCI in Patients with Acute Myocardial Infarction
张琳 1李寒雪 1韩英1
作者信息
- 1. 辽宁省金秋医院心血管内科一病房,沈阳 110000
- 折叠
摘要
目的 探讨达格列净联合沙库巴曲缬沙坦钠(ARNI)治疗急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)术后心力衰竭的疗效及对患者血清超敏 C 反应蛋白(hs-CRP)、N 端脑钠肽前体(NT-proBNP)水平的影响.方法 选取2022 年 1 月至 2024 年 1 月辽宁省金秋医院收治的AMI行PCI术后心力衰竭患者 60 例作为研究对象,根据治疗方法不同分为对照组与观察组,各30 例.对照组予以达格列净片治疗,观察组在对照组基础上联合ARNI治疗,比较两组的治疗效果.结果 治疗后观察组左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)低于对照组,左室射血分数(LVEF)高于对照组,差异有统计学意义(P＜0.05);治疗后观察组血清降钙素原(PCT)、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)、hs-CRP、NT-proBNP低于对照组(P＜0.05);观察组主要心血管不良事件发生率低于对照组(P＜0.05).结论 达格列净联合ARNI治疗AMI行PCI术后心力衰竭疗效较好,可有效改善患者的心脏功能,减轻炎症反应,且减少心血管不良事件发生.
Abstract
Objective To explore the efficacy of dagliflozin combined with sarcovalsartan sodium(ARNI)on heart failure after acute myocardial infarction(AMI)patients with heart failure after percutaneous coronary intervention(PCI)and its effect on serum hypersensitive C-reactive protein(hs-CRP)and n-terminal brain natriuretic peptide precursor(NT-proBNP).Methods Sixty AMI patients with heart failure after PCI treated in Jinqiu Hospital of Liaoning Province from January 2022 to January 2024 were selected as the study objects,and were divided into control group and observation group according to different treatment methods,with 30 cases in each group.The control group was treated with dagaglizin tablets,and the observation group was treated with ARNI on the basis of the control group.The therapeutic effect of the two groups was compared.Results After treatment,left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in observation group were lower than those in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the difference was statistically significant(P＜0.05).After treatment,serum procalcitonin(PCT),tumor necrosis factor α(TNF-α),interleukin-6(IL-6),hs-CRP and NT-proBNP in observation group were lower than those in control group(P＜0.05).The incidence of major cardiovascular adverse events in observation group was lower than that in control group(P＜0.05).Conclusion Daglizin combined with ARNI is effective in the treatment of heart failure in AMI patients after PCI,which can effectively improve the heart function of patients,reduce inflammation,and reduce the occurrence of cardiovascular adverse events.
关键词
达格列净/沙库巴曲缬沙坦钠/急性心肌梗死/经皮冠状动脉介入治疗/心力衰竭Key words
Dagliflozin/Sarcovalsartan sodium/Acute myocardial infarction/Percutaneous coronary intervention/Heart failure引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据